Advances in biochemical mechanisms of diabetic retinopathy

European Review for Medical and Pharmacological Sciences

Volumn 11, Issue 3, 2007, Pages 155-163

  Giusti, Cristiano ^a   Gargiulo, P ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biochemical mechanisms; Diabetes; Diabetic retinopathy; Retina

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANTIDIABETIC AGENT; ANTIOXIDANT; BENFOTIAMINE; CYTOKINE; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FIDARESTAT; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRIX METALLOPROTEINASE; POLYOL; PROTEIN KINASE C; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; SORBINIL; THIAMINE; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN; ZENARESTAT;

ANTICOAGULATION; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG MECHANISM; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT;

ANIMALS; CYTOKINES; DIABETIC RETINOPATHY; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPOPROTEINS; OXIDATIVE STRESS; POLYMERS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; THIAMINE;

EID: 34547534847     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. GARDNER TW, ANTONETTI DA, BARBER AJ, LANOUE KF, LEVISON SW. Diabetic retinopathy: More than meets the eye. Surv Ophthalmol 2002; 47: S253-S262.
2. AIELLO LP. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136:122-135.
3. FONG DS, AIELLO LP, FERRIS FL 3RD, KLEIN R. Diabetic retinopathy. Diabetes Care 2004; 27: 2540-2553.
4. FONG DS, AIELLO L GARDNER TW, KING GL, BLANKENSHIP G, CAVALLERANO JD, FERRIS FL 3RD, KLEIN R. American Diabetes Association. Retinopathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S84-S87.
5. PORTA M, ALLIONE A. Current approaches and perspectives in the medical treatment of diabetic retinopathy. Pharmacol Ther 2004; 103:167-177.
6. SCHAUMBERG DA, GLYNN RJ, JENKINS AJ, LYONS TJ, RIFAI N, MANSON JE, RIDKER PM, NATHAN DM. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 2005; 111: 2446-2453.
7. KILPATRICK ES, RIGBY AS, ATKIN SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29: 1486-1490.
8. STRATTON IM, CULL CA, ADLER AI, MATTHEWS DR, NEIL HA, HOLMAN RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: A prospective observational study (UKPDS 75). Diabetologia 2006; 49: 1761-1769.
9. OBROSOVA IG, PACHER P, SZABO C, ZSENGELLER Z, HIROOKA H, STEVENS MJ, YOREK MA. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 2005; 54: 234-242.
10. DAGHER Z, PARK YS, ASNAGHI V, HOEHN T, GERHARDINGER C, LORENZI M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004; 53: 2404-2411.
11. OYAMA T, MIYASITA Y, WATANABE H, SHIRAI K. The role of polyol pathway in high glucose-induced endothelial cell damages. Diabetes Res Clin Pract 2006 (in press).
12. WAUTIER MP, MASSIN P, GUILLAUSSEAU PJ, HULIBERTS M, LEVY B, BOULANGER E, LALOI-MICHELIN M, WAUTIER JL. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 2003; 29: 44-52.
13. WAUTIER MP, BOULANGER E, GUILLAUSSEAU PJ, MASSIN P, WAUTIER JL. AGEs, macrophage colony stimulating factor and vascular adhesion molecule blood levels are increased in patients with diabetic microangiopathy. Thromb Haemost 2004; 91: 879-885.
14. BOLTON WK, CATTRAN DC, WILLIAMS ME, ADLER SG, APPEL GB, CARTWRIGHT K, FOILES PG, FREEDMAN BI, RASKIN P, RATNER RE, SPINOWITZ BS, WHITTIER FC, WUERTH JP; ACTION I INVESTIGATOR GROUP. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40.
15. YATOH S, MIZUTANI M, YOKOO T, KOZAWA T, SONE H, TOYOSHIMA H, SUZUKI S, SHIMANO H, KAWAKAMI Y, OKUDA Y, YAMADA N. Antioxidants and an inhibitor of advanced glycation ameliorate death of retinal microvascular cells in diabetic retinopathy. Diabetes Metab Res Rev 2006; 22: 38-45.
16. AIELLO LP. The potential role of PKC b in diabetic retinopathy and macular edema. Surv Ophthalmol 2002; 47: S263-S269.
17. AIELLO LP, CAHILL MT, CAVALLERANO JD. Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy. Eye 2004; 18:117-125.
18. YAMAGISHI S, TAKEUCHI M. Inhibition of protein kinase C might be harmful to diabetic retinopathy. Med Hypotheses 2004; 63: 135-137.
19. WEGEWITZ U, GOHRING I, SPRANGER J. Novel approaches in the treatment of angiogenic eye disease. Curr Pharm Des 2005; 11: 2311-2330.
20. COMER GM, CIULLA TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 2004; 15: 508-518.
21. MATTEUCCI E, GIAMPIETRO O. Oxidative stress in families of type 1 diabetic patients. Diabetes Care 2001; 24: 167-168.
22. YOKOI M, YAMAGISHI SI, TAKEUCHI M, OHGAMI K, OKAMOTO T, SAITO W. MURAMATSU M, IMAIZUMI T, OHNO S. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in The vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 2005; 89: 673-675.
23. AMANO S, YAMAGISHI S, INAGAKI Y, NAKAMURA K, TAKEUCHI M, INOUE H, IMAIZUMI T. Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvasc Res 2005; 69: 45-55.
24. GIUSTI C, SCHIAFFINI R, BRUFANI C, PANTALEO A, VINGOLO EM, GARGIULO P. Coagulation pathways and diabetic retinopathy: Abnormal modulation in a selected group of insulin-dependent diabetic patients. Br J Ophthalmol 2000; 84: 591-595.
25. GIUSTI C. Retinopathy in juvenile diabetes: A 10-year (1990-2000) review. Pediatr Diabetes 2001; 2: 83-93.
26. GIUSTI C. Are phospholipid-binding antibodies implicated in the pathogenesis of diabetic microangiopathy? Med Hypotheses 2004; 63: 235-238.
27. BABAEI-JADIDI R, KARACHALIAS N, AHMED N, BATTAH S, THORNALLEY PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52:2110-2120.
28. HAMMES HP, DU X, EDELSTEIN D, TAGUCHI T, MATSUMURA T, JU Q, LIN J, BIERHAUS A, NAWROTH P, HANNAK D, NEUMAIER M, BERGFELD R, GIARDINO J, BROWNLEE M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. NaT Med 2003; 9: 294-299.
29. KARACHALIAS N, BABAEI-JADIDI R, KUPICH C, AHMED N, THORNALLEY PJ. High-dose thiamine therapy counters dyslipidaemia and advanced glycation in streptozotocin-induced diabetic rats. Ann NY Acad Sci 2005; 1043: 777-783.
30. BELTRAMO E, BERRONE E, BUTTIGUERI S, PORTA M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 2004; 20: 330-336
31. BERRONE E, BELTRAMO E, SOLIMINE C, APE AU, PORTA M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006; 281:9307-9313.
32. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, Klein RL. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/ EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-918.
33. JENKINS AJ, ROWLEY KG, LYONS TJ, BEST JD, HILL MA, KLEIN RL. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004; 10: 3395-3418.
34. KLEIN RL McHENRY MB, LOK KH, HUNTER SI, LE NA, JENKINS AJ, ZHENG D, SEMLER A, PAGE G, BROWN WV, LYONS TJ, GARVEY WT; DCCT/EDIC RESEARCH GROUP. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: Associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabet Complications 2005; 19: 18-25.
35. JENKINS AJ, LYONS TJ, ZHENG D, OTVOS JD, LACKLAND DT, MCGEE D, GARVEY WT KLEIN RL; DCC/EDIC RESEARCH GROUP. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications: Associations with gender and glycemia. Diabetes Care 2003; 26: 810-818.
36. AROCA PR, SALVAT M, FERNANDEZ J, MENDEZ I. Risk factors for diffuse and focal macular edema. J Diabetes Complications 2004; 18:211-215.
37. FUNATSU H, YAMASHITA H, SHIMIZU E, KOJIMA R, HORI S. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina 2001; 21: 469-477.
38. SHIMIZU E, FUNATSU H, YAMASHITA H, YAMASHITA T, HORI S. Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema. Jpn J Ophthalmol 2002; 46: 78-83.
39. FUNATSU H, YAMASHITA H, NOMA H, SHIMIZU E, MIMURA T, HORI S. Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. J Cataract Refract Surg 2002; 28: 1355.
40. FUNATSU H, YAMASHITA H, IKEDA T, MIMURA T, SHIMIZU E, HORI S. Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol 2003; 135: 321-327.
41. FUNATSU H, YAMASHITA H, IKEDA T, MIMURA T, EGUCHI S, HORI S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003; 110:1690-1696.
42. FUNATSU H, YAMASHITA H, NOMA H, MIMURA T, NAKAMURA S, SAKATA K, HORI S. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 2005; 243: 3-8.
43. MABERLEY D, CUI JZ, MATSUBURA JA. Vitreous leptin levels in retinal disease. Eye 2006; 20: 801-804.
44. ISHIZAKI E, TAKAI S, UEKI M, MAENO T, MARUICHI M, SUGIYAMA T, OKU H, IKEDA T, MIYAZAKI M. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol 2006; 141: 129-134.
45. JACQUEMINET S, BEN ABDESSELAM O, CHAPMAN MJ, NICOLAY N, FOGLIETTI MJ, GRIMALDI A, BEAUDEUX JL. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 2006; 367; 103-107
46. DESCAMPS FJ, MARTENS E, KANGAVE D, STRUYF S, GEBOES K, VAN DAMME J, OPDENAKKER G, ABU EL-ASRAR AM. The activated form of gelatinase B/ matrix metalloproteinase-9 is associated with diabetic vitreous hemorrhage. Exp Eye Res 2006; 83: 401-407.
47. MITAMURA Y, TAKEUCHI S, MATSUDA A, TAGAWA Y, MIZUE Y, NISHIHIRA J. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy, Br J Ophthalmol 2000; 84:636-639.
48. TASHIMO A, MITAMURA Y, NAGAI S, NAKAMURA Y, OHTSUKA K, MIZUE Y, NISHIHIRA J. Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy. Diabet Med 2004; 21:1292-1297.
49. ROLDAN-PALLARES M, ROLLIN R, MEDIERO A, MARTINEZ-MONTERO JC, FERNANDEZ-CRUZ A, BRAVO-LLATA C, FERNANDEZ-DURANGO R. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy. Mol Vis 2005; 11:461-471.
50. ZHU Q, Xu X, XIA X, Gu Q, Ho PC. Role of protein kinase C on the alteration of retinal endothelin-1 in streptozotocin-induced diabetic rats. Exp Eye Res 2005; 81: 200-206.
51. Shaw SG, Boden JP, Biecker E, Reichen J, Rothen B. Endothelin antagonism prevents diabetic retinopathy in NOD mice: A potential role of the angiogenic factor adrenomedullin. Exp Biol Med 2006; 231;1101-1105.
52. MASUZAWA K, JESMIN S, MAEDA S, ZAEDI S, SHIMOJO N, MIYAUCHI T, GOTO K. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina. Exp Biol Med 2006; 231;1090-1094.
53. AIELLO LP. Perspectives on diabetic retinopathy. New Engl J Med 2005; 353:839-841.
54. GARGIULO P, GIUSTI C, PIETROBONO D, LA TORRE D, DIACONO D, TAMBURRANO G. Diabetes mellitus and retinopathy. Dig Liver Dis 2004; 36: S101-S105.
55. GIUSTI C. Novel diagnostic and therapeutic approaches to the diabetic retinopathy. Eur Rev Med Pharmacol Sci 2001;5:155-166.